Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovation space that will allow drug developers to harness AI and computational science to solve therapeutic challenges.
Merck and Acceleron struck an $11.5 billion merger agreement, but before that, rare-disease focused Acceleron Pharma was wooed by multiple suitors, including pharma giant Bristol Myers Squibb.
Today’s approval was based on the Phase III KEYNOTE-826 trial that evaluated Keytruda and chemotherapy with or without bevacizumab compared to the same chemotherapy treatment.
If authorized, it could be available in the U.S. before the end of the year. It is also working to submit applications to other regulators worldwide.
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
Here’s a look at mRNA vaccines and their effectiveness and more COVID-19 news.
Newly appointed CEO Rob Davis must find a way to balance Merck’s portfolio before investors get (even more) antsy. And he is looking to be aggressive.
There is a noted discrepancy between the price the U.S. government has agreed to pay Merck for the drug and the actual manufacturing costs.
Investment firm Avoro Capital has raised concerns that the $180 per-share price Merck is paying Acceleron Pharma undervalues the rare-disease focused company.
JOBS
IN THE PRESS